A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis® in Subjects With Neovascular Age-related Macular Degeneration
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Samsung Bioepis
- 10 Oct 2017 Planned End Date changed from 1 Feb 2020 to 1 Jul 2020.
- 10 Oct 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2019.
- 10 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Apr 2018.